Masitinib is under clinical development by AB Science and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Masitinib’s likelihood of approval (LoA) and phase transition for Metastatic Pancreatic Cancer took place on 23 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Masitinib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Masitinib (AB-1010) is under development for the treatment of severe chronic obstructive pulmonary disease (COPD), amyotrophic lateral sclerosis, systemic mastocytosis, non resectable locally advanced or metastatic pancreatic cancer, gastrointestinal stromal tumor, adenocarcinoma of the gastroesophageal junction, androgen-independent prostate cancer, Alzheimer's disease, asthma, secondary progressive multiple sclerosis, primary progressive multiple sclerosis, ovarian cancer, metastatic epithelial ovarian cancer, primary peritoneal, primary fallopian tube cancer, relapsing-remitting multiple sclerosis, peripheral T-cell lymphomas including adult t-cell lymphoma/leukemia (human T-cell leukemia virus [HTLV] 1+), angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma ALK possitive and negative, peripheral T-cell lymphoma, extranodal natural killer (NK)/T-cell lymphoma, enteropathy-associated T-cell lymphoma, hepatosplenic T-cell lymphoma, subcutaneous panniculitis T-cell lymphoma and transformed mycosis fungoides. The drug candidate is administered orally. It is an ATP-binding site competitor. The drug candidate acts by inhibiting wild-type forms of c-KIT, Fyn, Lyn tyrosine kinase and platelet-derived growth factor receptor alpha and beta. Masitinib is a selective inhibitor of the tyrosine kinase inhibitor that targets KIT.
It is under development for the treatment of coronavirus disease 2019 (COVID-19), systemic mastocytosis, mast cell activation syndrome (MCAS) and amyotrophic lateral sclerosis.
The drug candidate was under development for the treatment of metastatic colorectal cancer, progressive supranuclear palsy, chronic plaque psoriasis, Parkinson's disease, indolent systemic mastocytosis, metastatic melanoma with and without JM mutation of c-KIT, glioblastoma multiforme, triple-negative breast cancer, metastatic breast cancer, gastric cancer, head and neck cancer, acute ischemic stroke, Dysthymia, depression, metastatic liver cancer, Crohn's disease (regional enteritis), hepatocellular carcinoma, castration resistant prostate cancer, relapsed/refractory multiple myeloma and non-small cell lung cancer and metastatic ovarian cancer as a second line therapy.
AB Science overview
AB Science (ABS) is a pharmaceutical company. It offers protein kinase inhibitors. The company’s lead compound Masitinib, is a orally administered tyrosine kinase inhibitor targeting mast cells and selected kinases, including c-Kit, PDGFR, and Lyn in several human indications such as oncology, inflammatory diseases, and central nervous system diseases. AB Science has developed several medicines for humans, on-going phase 2 and phase 3 studies in oncology and non-oncology diseases. The company is commercializing its lead product candidate in human and veterinary medicine. It has operations in France and the US. ABS is headquartered in Paris, France.
Quick View Masitinib LOA Data
|Highest Development Stage|